Trial Profile
HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 08 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 08 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 05 Sep 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.